Status:
COMPLETED
A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face
Lead Sponsor:
LEO Pharma
Collaborating Sponsors:
Bayer
Conditions:
Seborrheic Dermatitis on the Face
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.
Detailed Description
To test the efficacy and safety of azelaic acid 15% gel in the treatment of seborrheic dermatitis of the face
Eligibility Criteria
Inclusion
- \- Stable or exacerbating seborrheic dermatitis in the facial area
Exclusion
- Psoriasis
- Atopic dermatitis
- Facial acne and rosacea
- Dermatophytic skin infections
- Parkinson's disease
- Known immunosuppression; HIV infection
- Any condition requiring continuous systemic or topical corticosteroid or antimycotic therapy
- Continuous asthma inhalation treatment requiring \> 800 mg corticosteroids
- Any severe disease likely to interfere with the conduct or the planned termination of the study
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00408330
Start Date
December 1 2006
End Date
March 1 2007
Last Update
June 9 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Blankenfelde-Mahlow, Germany, 15831
2
Buchholz, Germany, 21244
3
Hamburg, Germany, 20354
4
Hamburg, Germany, 22049